Download PDF
Arzneimittelforschung 2011; 61(1): 8-13
DOI: 10.1055/s-0031-1296162
Antiallergic Drugs · Antiasthmatics · Antitussives · Bronchodilators · Bronchosecretogogues · Mucolytics
Editio Cantor Verlag Aulendorf (Germany)

Inhibitory effect of procaterol on exercise dynamic lung hyperinflation during the 6-min walk test in stable patients with chronic obstructive pulmonary disease

Masahiro Satake
1   Department of Physical Therapy, Akita University Graduate School of Health Sciences, Akita, Japan
,
Hitomi Takahashi
2   Department of Rehabilitation, Akita City General Hospital, Akita, Japan
,
Keiyu Sugawara
1   Department of Physical Therapy, Akita University Graduate School of Health Sciences, Akita, Japan
2   Department of Rehabilitation, Akita City General Hospital, Akita, Japan
,
Atsuoshi Kawagoshi
1   Department of Physical Therapy, Akita University Graduate School of Health Sciences, Akita, Japan
2   Department of Rehabilitation, Akita City General Hospital, Akita, Japan
,
Akira Tamaki
3   Department of Human Sciences, Kyoto University Graduate School of Human Health Sciences, Kyoto, Japan
,
Mitsunobu Homma
4   Department of Respiratory Medicine, Akita City General Hospital, Akita, Japan
,
Ryou Morita
5   Department of Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan
,
Kazuhiro Sato
5   Department of Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan
,
Masaaki Sano
5   Department of Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan
,
Takanobu Shioya
1   Department of Physical Therapy, Akita University Graduate School of Health Sciences, Akita, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2011 (online)

    Permissions and Reprints

Abstract

The purpose of this study was to evaluate the inhibitory effect of procaterol (procaterol hydrochloride, CAS 62929-91-3) on exercise dynamic lung hyperinflation during the 6-min walk test (6MWT) in stable chronic obstructive disease (COPD) patients. Fourteen patients with stable COPD who were referred to our clinic between July 2008 and October 2009 were evaluated in this study. After the inhalation of procaterol, values for the lung function test, including vital capacity, inspiratory capacity, forced vital capacity, and FEV1/FEV1pred showed a significant improvement. Compared to the baseline assessment, the 6-min walk distance increased by a mean of 20.5 m when measured after inhalation of procaterol (512.4 ± 90.7mvs. 532.9 ± 79.8 m, p < 0.05). During the 6MWT, inspiratory capacity decreased significantly with time. The inspiratory capacity after inhalation of procaterol was improved significantly compared with placebo. The Borg scale increased significantly during the 6MWT and was attenuated after inhaling procaterol hydrochloride, though the difference between the two groups was not statistically significant.

In the present study, there was a significant attenuation in exercise dynamic lung hyperinflation, suggesting the important role of the β2-receptor agonist procaterol in the treatment of COPD. It is therefore likely that most patients with COPD may derive considerable benefit from bronchodilator therapy with procaterol.

Key words

β2-Receptor agonist - Bronchodilator - CAS 62929-91-3 - Dyspnea - End-expiratory lung volume - Exercise dynamic lung hyperinflation - Procaterol hydrochloride - Six-minute walk test
 

  • References

  • 1 Fletcher CM, Pride NB. Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Chiba symposium. Thorax. 1984; 39: 81-5
    CrossrefPubMedSearch in Google Scholar
  • 2 National Heart, Lung and Blood Institute, National Institute of Health, the World Health Organization. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: www.goldcopd.com Accessed: 2010-2-1.
    PubMed
  • 3 O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis. 1993; 148: 1351-7
    PubMedSearch in Google Scholar
  • 4 Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996; 153: 967-75
    PubMedSearch in Google Scholar
  • 5 O'Donnell DE, Chau LKL, Bertley JC, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysilogic mechanism. Am J Respir Crit Care Med. 1997; 155: 109-15
    PubMedSearch in Google Scholar
  • 6 O'Donnell DE, D'Arsigny C, Fitzpatrick M, Webb KA. Exercise hypercapnea in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am J Respir Crit Care Med. 2002; 166: 663-8
    CrossrefPubMedSearch in Google Scholar
  • 7 Diaz O, Villafranca C, Ghezzo H, Borzone G, Levia A, Millic-Emil J et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J. 2000; 16: 269-75
    CrossrefPubMedSearch in Google Scholar
  • 8 O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164: 770-7
    CrossrefPubMedSearch in Google Scholar
  • 9 O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit CareMed. 1998; 158: 1557-65
    PubMedSearch in Google Scholar
  • 10 American Thoracic Society 2002ATS Statement: Guidelines for six-minute walk test. Am J Respir Crit Care Med. 2003; 166: 111-
    PubMedSearch in Google Scholar
  • 11 American Thoracic Society/American College of Chest Physicians 2003ATS/ACCP Statement: on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003; 167: 211-277
    CrossrefPubMedSearch in Google Scholar
  • 12 Sciurba F, Criner GJ, Lee SM, Mohsenifer Z, Shade D, Silvka W et al. Six-minute walk distance in chronic obstructive pulmonary disease. Reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med. 2003; 167: 1522-7
    CrossrefPubMedSearch in Google Scholar
  • 13 Yabuuchi Y, Yamahsita S, Tei SS. Pharmacological studies of OPC-2009, a newly synthesized selective beta adrenoceptor stimulant, in the bronchomotor and cardiovascular system of the anaesthetized dog. J Pharmacol Exp Ther. 1977; 202: 326-36
    PubMedSearch in Google Scholar
  • 14 Mirza ZN, Tokuyama K, Arakawa H, Kato M, Mochizuki H, Morikawa A. Inhaled procaterol inhibits histamine-induced airflow obstruction and microvascular leakage in guinea pig airways with allergic inflammation. Clin Exp Allergy. 1998; 28: 644-52
    CrossrefPubMedSearch in Google Scholar
  • 15 Sukisaki T, Senjyu H, Oishi K, Rikitomi N, Ariyoshi K. Single dose of inhaled procaterol has a prolonged effect on exercise performance of patients with COPD. Physiother Theory Prac. 2008; 24: 255-63
    PubMedSearch in Google Scholar
  • 16 Shioya T, Satake M, Sato K, Sano M, Sugawara K, Takahashi H et al. Long-term effect of the β2-receptor agonist procaterol on daily life performance and exercise capacity in patients with stable chronic obstructive pulmonary disease. Arzneimittelforschung. 2008; 58: 24-8
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1995; 152: S77-120
    PubMedSearch in Google Scholar
  • 18 Faggiano P, D'Aloia A, Gualeni A, Glordano A. Assessment of oxygen uptake during the 6-minute walking test in patients with heart failure: Preliminary experience with a portable device. Am Heart J. 1997; 13A: 203-6
    PubMedSearch in Google Scholar
  • 19 Schulz H, Helle S, Heck H. The validity of the telemetric system CORTEX X1 in the ventilatory and gas exchange measurement during exercise. Int J Sports Med. 1997; 18: 454-7
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Borg GA. Psychophysical basis of perceived exertion. Med Sci Sports Exerc. 1982; 14: 377-81
    PubMedSearch in Google Scholar
  • 21 Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME et al. Efficacy of salmeterol xinaforate in the treatment of COPD. Chest. 1999; 115: 957-965
    CrossrefPubMedSearch in Google Scholar
  • 22 Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002; 121: 1042-50
    CrossrefPubMedSearch in Google Scholar
  • 23 Fujimoto K, Yoshiike F, Yasuo M, Kitaguchi Y, Urushibara K, Kubo K et al. Effects of broncodilators on dynamic hyperinflation following hyperinflation in patients with COPD. Respirology. 2007; 12: 93-9
    CrossrefPubMedSearch in Google Scholar
  • 24 O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004; 24: 86-94
    CrossrefPubMedSearch in Google Scholar
  • 25 Honma I, Obata T, Shibuya M, Uchida M. Gate mechanism in breathlessness caused by chest wall vibration in humans. J Appl Physiol. 1984; 56 (1) 8-11
    PubMedSearch in Google Scholar
  • 26 Killan KJ, Bucens DD, Campbell EJM. Effect of breathing patterns on the perceived magnitude on added loads breathing. J Appl Physiol. 1982; 52: 578-84
    PubMedSearch in Google Scholar
  • 27 O'Donnell DE, McGuire M, Samis L, Webb KA. The impact of exercise recording on breathlessness in patients with severe chronic airflow limitation. Am J Respir Crit Care Med. 1995; 152: 2005-13
    PubMedSearch in Google Scholar
  • 28 Japanese Respiratory Society. COPD Guidelines for diagnosis and management. 3rd ed. 2009.
    PubMed